Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline Review, H1 2015

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline Review, H1 2015', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acute Renal Failure (ARF) (Acute Kidney Injury) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 9

Therapeutics Development 10

Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury)-Overview 10

Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury)-Comparative Analysis 11

Acute Renal Failure (ARF) (Acute Kidney Injury)-Therapeutics under Development by Companies 12

Acute Renal Failure (ARF) (Acute Kidney Injury)-Therapeutics under Investigation by Universities/Institutes 15

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Acute Renal Failure (ARF) (Acute Kidney Injury)-Products under Development by Companies 19

Acute Renal Failure (ARF) (Acute Kidney Injury)-Products under Investigation by Universities/Institutes 21

Acute Renal Failure (ARF) (Acute Kidney Injury)-Companies Involved in Therapeutics Development 22

ACROVIS biostructures GmbH 22

Adrenomed AG 23

Am-Pharma B.V. 24

Angion Biomedica Corp. 25

Bolder Biotechnology, Inc. 26

Cellmid Limited 27

DiaMedica Inc. 28

Digna Biotech, S.L. 29

F. Hoffmann-La Roche Ltd. 30

G1 Therapeutics, Inc. 31

Hadasit Medical Research Services & Development Ltd 32

Kringle Pharma, Inc. 33

NephroGenex, Inc. 34

Noorik Biopharmaceuticals AG 35

Nyken BV 36

Opsona Therapeutics Ltd. 37

Quark Pharmaceuticals, Inc. 38

STATegics, Inc. 39

Thrasos, Inc. 40

Torrent Pharmaceuticals Limited 41

Acute Renal Failure (ARF) (Acute Kidney Injury)-Therapeutics Assessment 42

Assessment by Monotherapy Products 42

Assessment by Target 43

Assessment by Mechanism of Action 45

Assessment by Route of Administration 47

Assessment by Molecule Type 49

Drug Profiles 51

adrecizumab-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

BB-3-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

BBT-030-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

BBT-045-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

CAB-101-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

cardiotrophin-1-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Cell Therapy to Activate Wnt7b for Kidney Injury-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

CXA-10-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

DM-199-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

HYPER-IL-6-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

KP-100IT-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

MTP-131-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

N-003-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

NOXD-21-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

NYK-1341-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

OPN-305-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Pyridoxamine Dihydrochloride-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

QPI-1002-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

R-190-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Recombinant Human Alkaline Phosphatase-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

RO-6839328-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Small Molecule to Activate Heat Shock Protein 70 (Hsp70) for Delayed Graft Function-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Small Molecule to Inhibit HDAC for Acute Kidney Injury-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Small Molecules for Acute Renal Failure-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

STSE-15-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

THR-184-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

TRC-160334-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Acute Renal Failure (ARF) (Acute Kidney Injury)-Recent Pipeline Updates 90

Acute Renal Failure (ARF) (Acute Kidney Injury)-Dormant Projects 102

Acute Renal Failure (ARF) (Acute Kidney Injury)-Discontinued Products 103

Acute Renal Failure (ARF) (Acute Kidney Injury)-Product Development Milestones 104

Featured News & Press Releases 104

Dec 15, 2014: Complexa Initiates Phase 1B Study of CXA-10 in Acute Kidney Injury 104

Nov 13, 2014: AM-Pharma Presents Preclinical Data On Mode-Of-Action For RecAP In Acute Kidney Injury 104

Sep 16, 2014: Thrasos Announces Successful Formal Interim Analysis and Clinical Update for Phase 2 Study of THR-184 for Acute Kidney Injury 105

Jul 01, 2014: Quark Announces Completion of Phase II Trial Evaluating QPI-1002 for Prevention of Delayed Graft Function in Kidney Transplant Patients 106

May 01, 2014: Complexa Initiates First Clinical Trial of CXA-10 for Acute Kidney Injury 106

Mar 26, 2014: AM-Pharma announces positive Phase I data on recAP for Acute Kidney Injury 107

Feb 04, 2014: FDA Grants Thrasos Fast Track Designation for THR-184 in Acute Kidney Injury 107

Jan 28, 2014: American Journal of Kidney Disease publishes review article of Alkaline Phosphatase 108

Nov 08, 2013: AM-Pharma Presents Positive Data from recAP Preclinical Study at ASN Meeting 108

Sep 23, 2013: AM-Pharma Returns to Clinic with Phase I Trial of New Recombinant Human Alkaline Phosphatase to Treat Acute Kidney Injury 109

Appendix 110

Methodology 110

Coverage 110

Secondary Research 110

Primary Research 110

Expert Panel Validation 110

Contact Us 111

Disclaimer 111

List of Tables

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2015 10

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury)-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Comparative Analysis by Unknown Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by ACROVIS biostructures GmbH, H1 2015 22

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Adrenomed AG, H1 2015 23

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Am-Pharma B.V., H1 2015 24

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Angion Biomedica Corp., H1 2015 25

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Bolder Biotechnology, Inc., H1 2015 26

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Cellmid Limited, H1 2015 27

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by DiaMedica Inc., H1 2015 28

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Digna Biotech, S.L., H1 2015 29

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 30

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by G1 Therapeutics, Inc., H1 2015 31

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015 32

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Kringle Pharma, Inc., H1 2015 33

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by NephroGenex, Inc., H1 2015 34

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Noorik Biopharmaceuticals AG, H1 2015 35

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Nyken BV, H1 2015 36

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Opsona Therapeutics Ltd., H1 2015 37

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Quark Pharmaceuticals, Inc., H1 2015 38

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by STATegics, Inc., H1 2015 39

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Thrasos, Inc., H1 2015 40

Acute Renal Failure (ARF) (Acute Kidney Injury)-Pipeline by Torrent Pharmaceuticals Limited, H1 2015 41

Assessment by Monotherapy Products, H1 2015 42

Number of Products by Stage and Target, H1 2015 44

Number of Products by Stage and Mechanism of Action, H1 2015 46

Number of Products by Stage and Route of Administration, H1 2015 48

Number of Products by Stage and Molecule Type, H1 2015 50

Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics-Recent Pipeline Updates, H1 2015 90

Acute Renal Failure (ARF) (Acute Kidney Injury)-Dormant Projects, H1 2015 102

Acute Renal Failure (ARF) (Acute Kidney Injury)-Discontinued Products, H1 2015 103

List of Figures

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2015 10

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury)-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 42

Number of Products by Top 10 Targets, H1 2015 43

Number of Products by Stage and Top 10 Targets, H1 2015 43

Number of Products by Top 10 Mechanism of Actions, H1 2015 45

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 46

Number of Products by Top 10 Routes of Administration, H1 2015 47

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 48

Number of Products by Top 10 Molecule Types, H1 2015 49

Number of Products by Stage and Top 10 Molecule Types, H1 2015 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ACROVIS biostructures GmbH

Adrenomed AG

Am-Pharma B.V.

Angion Biomedica Corp.

Bolder Biotechnology, Inc.

Cellmid Limited

DiaMedica Inc.

Digna Biotech, S.L.

F. Hoffmann-La Roche Ltd.

G1 Therapeutics, Inc.

Hadasit Medical Research Services & Development Ltd

Kringle Pharma, Inc.

NephroGenex, Inc.

Noorik Biopharmaceuticals AG

Nyken BV

Opsona Therapeutics Ltd.

Quark Pharmaceuticals, Inc.

STATegics, Inc.

Thrasos, Inc.

Torrent Pharmaceuticals Limited

Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutic Products under Development, Key Players in Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics, Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Overview, Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline, Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com